Participants in the study will receive either Sovateltide or a matching placebo. Sovateltide is administered as an injection directly into the bloodstream. The study will follow participants for a period of 90 days after they are randomly assigned to receive either the treatment or the placebo. During this time, researchers will assess the participants’ recovery and overall health.

The main goal of the study is to see if Sovateltide can lead to a good recovery, as measured by a scale that evaluates the level of disability or dependence in daily activities. The study will also look at other aspects of recovery, such as changes in quality of life and the occurrence of any additional strokes or health issues. Participants will be monitored closely to ensure their safety throughout the study period.

The purpose of the study is to determine whether stopping these blood thinners is as safe and effective as continuing them in preventing major cardiovascular events, such as another stroke or heart attack, three to ten years after the initial stroke. Participants in the study will be randomly assigned to either continue or stop their antiplatelet therapy. Some participants may receive a placebo, which looks like the medication but does not contain any active ingredients. The study will monitor participants over a period of time to observe any major health events, including strokes, heart attacks, or other serious conditions.

Throughout the study, researchers will also assess other factors such as the risk of major bleeding, overall survival, cost-effectiveness, and quality of life. The study aims to provide valuable information on the long-term management of young stroke patients and help guide future treatment decisions. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in the study will take Deferiprone in the form of film-coated tablets. The treatment will be administered daily at a low dose for a period of six months. The study will compare the effects of this treatment on iron levels in the brain with those observed in previous research where no treatment was given. The study will involve taking MRI scans, which are imaging tests that help visualize the brain, at the beginning and end of the six-month period to assess changes in iron levels.

Throughout the study, participants will be monitored for any changes in their condition, including their physical and cognitive abilities, as well as their mood. These assessments will help determine the overall impact of Deferiprone on recovery after a stroke. The study aims to provide valuable insights into whether this medication can be beneficial in preventing further brain damage following a stroke.

The purpose of the study is to evaluate how well these treatments work in preventing new ischemic lesions in the brain, which are areas of tissue damage caused by a lack of blood flow. These lesions will be monitored using MRI scans of the brain, taken within 24 hours after the procedure and again after three months. The study will also look at other outcomes, such as any new symptoms of stroke or bleeding events, and assess the overall health and cognitive function of the participants over the three-month period.

Participants in the study will be monitored closely, with regular check-ups and assessments to ensure their safety and to gather data on the effectiveness of the treatments. The trial aims to provide valuable information on the best strategy for preventing complications in patients with atrial fibrillation who have undergone LAAC, ultimately helping to improve patient care and outcomes.

The purpose of the study is to evaluate how these injections can help reduce unwanted muscle contractions in the arm, particularly when trying to extend the elbow. Participants in the study will receive injections of the medication into the muscles that flex the elbow. The study will observe changes in muscle activity and movement ability over time, comparing results before and after the treatment.

Throughout the study, participants will undergo various assessments to measure muscle function and movement. These assessments will help determine the effectiveness of the treatment in improving arm function after a stroke. The study aims to provide valuable insights into how botulinum toxin type A can be used to enhance recovery and improve quality of life for individuals affected by stroke-related muscle issues.

The purpose of the study is to compare the brain activity related to these systems in two groups of people who have had a stroke: those who experience apathy and those who do not. Participants will be observed 3 to 7 months after their stroke. The study will involve using imaging techniques to measure how these substances bind in the brain, which can provide insights into the functioning of the cholinergic and dopaminergic systems.

Throughout the study, participants will receive injections of the substances and undergo imaging procedures, such as MRI (Magnetic Resonance Imaging), to assess brain activity and connectivity. The study will also look at other factors like the severity of apathy and blood flow in the brain. This research aims to enhance understanding of how these brain systems contribute to apathy, potentially leading to better treatments in the future.

The purpose of the study is to compare the effects of these NOACs with no anticoagulation treatment on preventing certain health issues. These issues include non-hemorrhagic stroke, which is a type of stroke not caused by bleeding in the brain, and systemic embolism, which is when a blood clot travels through the bloodstream and causes blockages. The study also looks at vascular mortality, which refers to deaths related to blood vessel problems, and other conditions like heart attacks and blood clots in the veins.

Participants in the study will be randomly assigned to receive either one of the NOACs or no anticoagulation treatment. The study will last for a period of up to 120 days, during which the health of the participants will be monitored to see how well the medications work in preventing the mentioned health issues. The goal is to gather information that could help improve treatment options for patients who experience atrial fibrillation after surgery.

The purpose of the study is to evaluate how effective erythromycin lactobionate is in decreasing the stomach’s antral surface area, which is the part of the stomach closest to the small intestine. This is important because having a full stomach can complicate medical procedures. Patients who are found to have significant stomach contents, as determined by an ultrasound scan, will be included in the study. The trial will monitor changes in the stomach area before and after the thrombectomy procedure to assess the medication’s impact.

Throughout the study, various observations will be made, such as the frequency of patients with reduced stomach size and any changes in medical management strategies due to the ultrasound findings. The trial will also track any complications that may arise during the thrombectomy procedure, such as low blood pressure or breathing difficulties, and any side effects related to the administration of erythromycin lactobionate. The study is designed to provide valuable insights into the potential benefits of using this medication in stroke patients undergoing emergency procedures.

Participants in the study will receive either the medication or a placebo after their mechanical thrombectomy procedure. The study will monitor the patients over a period of time to assess the effects of the treatment. This includes checking the blood flow in the brain using imaging techniques like CT Perfusion, which is a type of scan that shows how blood is moving through the brain. The study will also evaluate the patients’ recovery and ability to perform daily activities after 90 days.

The purpose of this research is to explore whether the combination of mechanical thrombectomy and Alteplase can lead to better recovery outcomes for patients who have suffered an acute ischemic stroke. By understanding the potential benefits of this treatment approach, the study aims to improve the care and recovery of stroke patients in the future.

Participants in the study will receive either tranexamic acid or a placebo, which is a substance that looks like the medication but does not have any active ingredients. The study will involve giving the treatment through an injection or infusion, which means the medication is delivered directly into the bloodstream. The study will monitor the effects of the treatment on early death within the first seven days after the stroke and also look at how it affects the patient’s ability to live independently six months later.

The trial aims to determine if tranexamic acid should be used in regular medical practice for treating ICH. By participating in this study, researchers hope to gather important information that could improve treatment options for people who suffer from this type of stroke in the future.

The purpose of the study is to explore the relationship between levels of a protein called ficolin-2 in the blood and inflammation in the brain and carotid arteries. Participants will undergo imaging with PET/MRI to assess inflammation. The study will involve taking blood samples to measure ficolin-2 levels and performing imaging tests to observe the condition of the carotid arteries and brain. The imaging will help identify features such as the size of any brain infarcts (areas of tissue damage due to lack of blood flow) and any changes in the carotid arteries, such as the presence of bleeding within the artery walls or damage to the protective layer of the artery.

Throughout the study, participants will have their blood tested and undergo imaging at specific times to monitor changes. The study aims to provide insights into how ficolin-2 levels relate to inflammation in the brain and carotid arteries, which could help improve understanding and treatment of conditions like stroke and transient ischemic attack. The trial is expected to continue until the end of 2024.